RxDoctor Payments DataLook up a doctor →

Jennifer Gilligan

Internal Medicine · Atlanta, GANPI 1376730887

Payments from drug & device makers

$161,555in general payments, 2019–2025

Across 812 payments — averaging $198.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$144K
  • Sanofi-aventis U.S. LLC$6K
  • Novo Nordisk$2K
  • Amgen$2K
  • Abbott$934
  • Xeris Pharmaceuticals, Inc.$816
  • plus $6K from 42 others

What the payments were for

  • Consulting fees$6,3284%
  • Speaking & faculty fees$129,50080%
  • Travel & lodging$10,2496%
  • Food & beverage$15,46310%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$161,555 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$98,289
Medicare patients
417
Services billed
1,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide539$882,508
KorlymMifepristone12$726,119
JardianceEmpagliflozin225$249,476
TrulicityDulaglutide99$167,049
MounjaroTirzepatide121$165,113
Tresiba Flextouch U-100Insulin Degludec126$95,558
RybelsusSemaglutide43$81,463
JanuviaSitagliptin Phosphate65$71,181
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog97$58,830
Tresiba Flextouch U-200Insulin Degludec56$55,740
FarxigaDapagliflozin Propanediol41$42,625
TradjentaLinagliptin45$38,697
ProliaDenosumab21$36,235
Humulin R U-500Insulin Regular, Human17$36,190
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$24,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,712$963,970582 claims
Corcept TherapeuticsKorlym$377$726,11912 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$144,448$336,082235 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy$419$321,180296 claims
MerckJanuvia, Janumet$140$84,63877 claims
AstraZenecaFarxiga$299$42,62541 claims
AmgenProlia$1,590$36,23521 claims
AbbVieSynthroid$305$19,893209 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$5,986$12,44018 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$458$7,325559 claims
IBSA Pharma Inc.Tirosint$137$4,81719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →